Skip to main content

Table 1 Patient and treatment summary

From: High-dose-rate brachytherapy for soft tissue sarcoma in children: a single institution experience

Patient/age

Diagnosis

Grade*

Implant site

Margins

CMT

Group*

HDRBT (Gy)

EBRT (Gy)

Local failure

Distant failure

DFS (mo)

female/9

RMSE

III

Head neck

Negative

Yes

I

18

41.4

  

159

female/16

Synovial sarcoma

III

extremity

Negative

None

I

24

None

  

19

Female/2

ASPS

II

Extremity

Negative

Yes

I

24

None

  

21

Female/14

Synovial sarcoma

II

Extremity Hand

Positive

None

II

24

41.4

 

Lung

45

Male/5

Synovial sarcoma

II

Head neck

Negative

Yes

I

24

None

  

79

Female/12

ASPS

III

Extremity

Negative

None

I

18

30.6

  

29

Female/2

RMSE

II

Pelvic

negative

Yes

I

24

None

  

54

Male/4

ASPS

II

Extremity

Positive

Yes

II

24

None

  

143

female/1

ASPS

III

Extremity

Positive

Yes

II

30

None

 

Lung

18

Male/2

fibrosarcoma

II

Pelvic

Negative

Yes

I

40

None

  

83

Female/11

Synovia sarcomal

III

Extremity

Positive

Yes

II

24

50

  

141

Female/9

RMSE

III

Head Neck

Positive

Yes

III

18

43.2

  

65

Female/12

RMSE

III

Head Neck

positive

Yes

III

18

45

  

94

Male/2

ASPS

II

Pelvic

Negative

Yes

I

21

None

  

12

Male/9

Synovial sarcoma

II

Extremity

Negative

Yes

I

30

None

  

114

Female/12

RMS pleomorfic

II

Extremity

Negative

None

I

21

None

  

80

Female/3

Sarcoma indiferency

III

Extremity

Negative

Yes

I

21

41.4

 

Lung

38

female/16

ASPS

III

Extremity

Positive

Yes

III

24

50.0

yes

NCS

18

  1. *Intergroup Rhabdomyosarcoma Study (IRS) staging used for both rhabdomyosarcomas and nonrhabdomyosarcomas. ASPS= soft tissue sarcoma alveolar, RMSE= Rhabdomyosarcoma embryonary